Lipocine vs Oramed Pharmaceuticals
LPCN and ORMP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LPCN and ORMP compare
Oramed Pharmaceuticals is the larger company, worth 13 times as much as Lipocine ($172M against $13.1M).
Oramed Pharmaceuticals pays a dividend yielding 6.1%; Lipocine does not pay one.
Oramed Pharmaceuticals scores higher on the StockData Score (12 against 11 for Lipocine), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LPCN | ORMP |
|---|---|---|
| Size and price | ||
| Market cap | $13.1M | $172M |
| Share price | $1.59 | $4.13 |
| Change, 1 year | −45.0% | 81.1% |
| Change, 5 years | −92.0% | −84.4% |
| Beta (5Y) | 0.65 | 1.44 |
| Employees | 14 | 13 |
| StockData Score | ||
| Total score | 11 | 12 (better) |
| Valuation score | 3 (better) | 2 |
| Growth score | 1 | 1 |
| Performance score | 2 (better) | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | – | 1.0× |
| P/S | 3.5× | – |
| P/B | 0.6× | – |
| PEG | – | 0.04 |
| FCF yield | – | −3.0% |
| Fair value | $3.42 | – |
| Margin of safety | 53.6% | – |
| Growth | ||
| Revenue growth (TTM) | −13.4% | – |
| Revenue growth, 5Y average | – | −5.8% |
| EPS growth, 5Y average | – | 12.8% |
| Profitability | ||
| Operating margin | −269% | – |
| Net margin | −249% | – |
| Return on equity | −52.9% | 113% (better) |
| Return on invested capital | – | −8.4% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 11.36 (better) | 4.98 |
| Altman Z-score | −9.37 | 1.96 (better) |
| Piotroski F-score | 1 | 3 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 6.1% |
| Years of dividend growth | – | 0 |
| Buyback yield | −123% | – |
| Shareholder yield | −123% | 6.1% (better) |
| Ownership | ||
| Held by institutions | 36.2% | 40.3% |
| Held by insiders | 8.4% | 23.9% |
| Insider net buying, 12 months | $517K (better) | −$1.2M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 4.3% | 4.2% |
Go deeper
- LPCN stock overview
- LPCN income statement
- LPCN valuation and score
- ORMP stock overview
- ORMP income statement
- ORMP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.